$11.90
0.34% today
Nasdaq, Apr 03, 06:13 pm CET
ISIN
US86889P1093
Symbol
SRZN

Surrozen Inc Stock price

$11.86
+1.16 10.84% 1M
+0.88 8.01% 6M
-2.49 17.35% YTD
+2.39 25.24% 1Y
-38.39 76.40% 3Y
-139.79 92.18% 5Y
-139.79 92.18% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.74 6.65%
ISIN
US86889P1093
Symbol
SRZN
Sector

Key metrics

Market capitalization $38.91m
Enterprise Value $12.81m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.20
P/S ratio (TTM) P/S ratio 3.65
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $10.66m
EBIT (operating result TTM) EBIT $-25.54m
Free Cash Flow (TTM) Free Cash Flow $-17.65m
Cash position $34.57m
EPS (TTM) EPS $-21.27
Short interest 6.03%
Show more

Is Surrozen Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Surrozen Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Surrozen Inc forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Surrozen Inc forecast:

Buy
100%

Financial data from Surrozen Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
11 11
-
100%
- Direct Costs 1.44 1.44
43% 43%
14%
9.21 9.21
465% 465%
86%
- Selling and Administrative Expenses 14 14
3% 3%
128%
- Research and Development Expense 20 20
20% 20%
185%
-24 -24
40% 40%
-226%
- Depreciation and Amortization 1.44 1.44
43% 43%
14%
EBIT (Operating Income) EBIT -26 -26
41% 41%
-240%
Net Profit -64 -64
48% 48%
-596%

In millions USD.

Don't miss a Thing! We will send you all news about Surrozen Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Surrozen Inc Stock News

Negative
24/7 Wall Street
one day ago
After struggling through a rough patch, the biotech industry seems to be staging a comeback.
Neutral
GlobeNewsWire
3 days ago
SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today provided fourth quarter and full year 2024 financial results and business updates.
Neutral
GlobeNewsWire
10 days ago
Company prioritizes ophthalmology pipeline programs with potential to provide new or improved treatment options in multiple severe and disabling eye diseases  Announces an oversubscribed financing of $175 million in gross proceeds, which funds multiple ophthalmology programs through phase 1 safety, tolerability and efficacy studies Company discontinues clinical development of SZN-043 in severe ...
More Surrozen Inc News

Company Profile

Surrozen, Inc. is a preclinical stage biotechnology company, which engages in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. It is also focused on developing tissue-specific antibodies designed to engage the body's existing biological repair mechanisms with potential application across multiple disease areas, including inflammatory bowel disease, hepatitis, eye diseases, hearing loss, lung and airway diseases, and certain neurological disorders. The company was founded on August 12, 2015 and is headquartered in South San Francisco, CA.

Head office United States
CEO Craig Parker
Employees 41
Founded 2015
Website www.surrozen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today